Adela C. N.
- Country
- Spain
- Department
- #3106:Onco Hematología
Research Overview
- Safety and Feasibility of AloCelyvir Combined with Autologous IL‑7/15/21‑Expanded TILs in Children/Young Adults with High‑Risk Relapsed/Refractory Neuroblastoma
- Phase 1B Evaluation of Crizotinib Alone or with Temsirolimus in Pediatric ALK, ROS1, or MET-Positive Malignancies
- Evaluation of Chemotherapy Regimens Including Cisplatin, Cyclophosphamide, and Etoposide in Pediatric and Young Adult Ependymoma Treatment
Data & Insights
Has run more than one trial at 67 of 179 partner sites.
Specializations
Neuroblastoma Research
The investigator specializes in treating high-risk neuroblastoma, with particular focus on novel therapeutic approaches including immunotherapy combinations and targeted treatments. Their work encompasses both newly diagnosed cases and refractory disease.
- Antibody-based therapies
- Induction chemotherapy optimization
- Refractory disease management
Glioma Studies
The investigator focuses on developing treatments for various types of pediatric gliomas, including innovative approaches for both low-grade and diffuse intrinsic pontine gliomas. Their research encompasses targeted molecular therapies and novel therapeutic combinations.
- Diffuse midline gliomas
- Low-grade glioma treatment
- RAF-altered tumors
Molecular-Targeted Therapies
The investigator conducts research on precision medicine approaches for pediatric cancers, particularly focusing on ALK-positive malignancies and other molecularly defined tumors. Their work includes studies of various targeted agents across multiple tumor types.
- ALK-positive tumors
- Inflammatory myofibroblastic tumors
- Molecular stratification studies
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.